entertainment -WSS

entertainment

author：Wikipedia 2025-08-11 08:01:17 - browse：8

JOSEPH PREZIOSO/AFP via Getty Images

Late-stage trial results for a pain medication developed by Vertex Pharmaceuticals reinforced experts’ sense that the drug was both safe and offered modest pain relief. But the findings also prompted fresh debate on Tuesday about how widely used the therapy would be should it win regulatory approval.

The company reported that its small molecule drug, VX-548, outperformed placebo in a pair of pain relief trials that recruited patients who had gotten an abdominoplasty (tummy tuck) or bunion surgery. The study also found that the drug was generally safe, with fewer patients on the medication reporting adverse events than those who had taken a placebo. But there was a catch: VX-548 didn’t outperform a combination of acetaminophen and the opioid hydrocodone, a key secondary endpoint. And in the bunionectomy study, the opioid comparator beat VX-548 on pain relief.

“While this study was not explicitly designed to test VX-548 vs. the opioid comparator, this may complicate the prescribing decision in the acute setting, where patients often take a short course of treatment and efficacy is a primary consideration,” Stifel market analyst Paul Matteis wrote in a note to investors, adding that results from three Phase 3 studies were positive overall.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Genentech weighs delaying cancer therapy after drug pricing law

knowledge

WSS

Maui funeral service workers on devastation of fires: 'I'm in shock'

TB outbreak tied to bone grafts underscores testing shortcomings

Neuroscience’s long legacy of racism

Pharma budget tightening trickles down to Doximity

Orchard's therapy for neuron disease in children wins FDA approval

Neuroscience’s long legacy of racism

leisure time

entertainment

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Novo acquires Inversago for up to $1 billion

The cancer drug shortage isn’t new — and neither are the solutions

Leading voice in opioid treatment defends methadone clinic system

Walensky prepares to leave CDC — and Congress — behind

Methadone treatment changes are coming. Do they go far enough?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

5 to watch: Tech startups trying to solve health care's staffing crisis

Wikipedia

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

Colonoscopy prep: Liquid

CDC overhauls leadership of center that led response to Covid

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

App could help diagnose ear infections more accurately — and at home

An innovative path out of biotech’s “valley of death”

explore

leisure time

knowledge

leisure time